

Draft

## GOVERNMENT REGULATION

of 2023,

### **amending the Government Regulation No 463/2013 Coll. on schedules of addictive substances, as amended**

Pursuant to Section 44c(1) and (2) of Act No. 167/1998 Coll., on Addictive Substances and on Amendments to Certain Other Acts, as amended by Act No. 273/2013 Coll. and Act No. 366/2021 Coll., the Government hereby orders:

#### Article I

Government Regulation No. 463/2013 Coll., on lists of addictive substances, as amended by Government Regulation No. 243/2015 Coll., Government Regulation No. 46/2017 Coll., Government Regulation No. 30/2018 Coll., Government Regulation No. 242/2018 Coll., Government Regulation No. 184/2021 Coll. and Government Regulation No. 159/2022 Coll., is amended as follows:

1. At the end of footnote 3, the sentence is added to a separate line

‘Commission Delegated Directive (EU) 2022/1326 of 18 March 2022 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of new psychoactive substances in the definition of a drug.’

2. In the table in Annex 3, a new row is inserted above the row in which the word 'Butonitazene' appears in the column headed 'International non-proprietary name (INN) in the Czech language' and in which the word 'Brorphine' appears in the column headed 'International non-proprietary name (INN) in the Czech language', in the column headed 'Other international non-proprietary name or other common name' the word 'brorphine' is entered and in the column headed 'IUPAC chemical name' the word '3-{1-[1-(4-bromophenyl)ethyl]piperidine-4-yl}-1H-benzimidazole-2-one' is entered.
3. In the table in Annex 3, a new row is inserted above the row in which the word 'Etorphine' appears in the column headed 'International non-proprietary Name (INN) in Czech', in which the word 'Etonitazepine' appears in the column headed 'International non-proprietary name (INN) in Czech' and the word '2-[(4-ethoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzoimidazole' appears in the column headed 'IUPAC chemical name'.
4. In the table in Annex 3, a new row is inserted above the row in which the word 'Cannabis resin' appears in the column headed 'International non-proprietary Name (INN) in Czech', in which the word 'Protonitazene' appears in the column headed 'International non-proprietary name (INN) in Czech' and the word 'N,N-diethyl-5-

nitro-2-[(4-propoxyphenyl)methyl]-1-*H*-benzimidazole-1-ethanamine)' appears in the column headed 'IUPAC chemical name'.

5. In Table 4, a new row is inserted above the row in which the text '7-MAPB' appears in the column headed 'Other international non-proprietary name or other generic name', in which the column headed 'International non-proprietary name (INN) in Czech' contains the word '7-Hydroxymitragynine' and the column headed 'IUPAC chemical name' contains the word 'Methyl (2E)-2-[(2S, 3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12b-octa hydroindole[2,3-a]chinolizine-2-yl]-3-methoxyprop-2-enoate'.
6. In the table in Annex 4, a new row is inserted above the row in which the word 'ADB-FUBINACA' appears in the column headed 'Other international non-proprietary name or other generic name', in which the word 'ADB-BUTINACA' appears in the column headed 'Other international non-proprietary name or other common name' and the word '*N*-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-butyl-1*H*-indazole-3-carboxamide)' appears in the column headed 'IUPAC chemical name'.
7. In the table in Annex 4, a new row is inserted above the row in which the word 'Hexedron' appears in the column headed 'International Non-Proprietary Name (INN) in the Czech language', in which the word 'Hexahydrocannabinol' appears in the column headed 'International Non-Proprietary Name (INN) in the Czech language', and the abbreviation 'HHC' appears in the column headed 'Other International Non-Proprietary Name or Generic Name', in the column headed 'IUPAC chemical name', the word '(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[*c*]chromen-1-ol' and in the column headed 'Note', the words 'With the exception of HHC, if it is present in less than 0,3 % in the industrial hemp plant, industrial hemp, hemp extract and tincture and industrial hemp preparation.'.
8. In the table in Annex 4, a new row is inserted above the row in which the text 'LTI-701' appears in the column headed 'Other international non-proprietary name or other generic name' and the word 'Kratom' appears in the column headed 'International non-proprietary name (INN) in Czech'.
9. In the table in Annex 4, a new row is inserted above the row in which the word 'm-Chlorophenylpiperazine' appears in the column headed 'International Nonproprietary Name (INN) in Czech', in which the word 'Mitragynine' appears in the column headed 'International non-proprietary name (INN) in Czech' and the word 'Methyl (16E)-9,17-dimethoxy-16,17-didehydro-20 $\beta$ -corynan-16-carboxylate' appears in the column headed 'IUPAC chemical name'.
10. In the table of Annex no. 4, a new row is inserted above the row in which the word 'Tetrahydrocannabinol' appears in the column headed 'International non-proprietary name (INN) in Czech', in which the word 'Tetrahydrocannabiphorol' appears in the column headed 'International non-proprietary name (INN) in Czech', and the abbreviation 'THCP' appears in the column headed 'Other international non-proprietary name or common name', in the column headed 'Chemical name according to IUPAC' the word '(6aR,10aR)-3-heptyl-6,6,9-trimethyl-6a,7,8,10a-

tetrahydrobenzo[c]chromen-1-ol' and in the column headed 'Note' the words 'With the exception of the substance THCP when present in the plant of industrial hemp, industrial hemp, hemp extract and tincture and the preparation of industrial hemp in a quantity of less than 0,3 %.'

Article II  
**Technical regulation**

This Regulation has been notified in accordance with Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services.

Article III  
**Validity**

This Government Regulation shall enter into force on the first day of the calendar month following its promulgation, with the exception of Article I(4), (6) to (9), which shall enter into force on the first day of the second calendar month following its promulgation.

Prime Minister:

Deputy Prime Minister and Minister for Health